ZA978099B - Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance. - Google Patents
Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance.Info
- Publication number
- ZA978099B ZA978099B ZA9708099A ZA978099A ZA978099B ZA 978099 B ZA978099 B ZA 978099B ZA 9708099 A ZA9708099 A ZA 9708099A ZA 978099 A ZA978099 A ZA 978099A ZA 978099 B ZA978099 B ZA 978099B
- Authority
- ZA
- South Africa
- Prior art keywords
- controlled release
- oral administration
- pharmaceutical compositions
- release pharmaceutical
- active substance
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title abstract 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001597 nifedipine Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 title 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT96MI001983A IT1284604B1 (it) | 1996-09-27 | 1996-09-27 | Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA978099B true ZA978099B (en) | 1998-03-27 |
Family
ID=11374935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9708099A ZA978099B (en) | 1996-09-27 | 1997-09-09 | Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5871775A (xx) |
| EP (1) | EP0838218B1 (xx) |
| JP (1) | JPH10152440A (xx) |
| CN (1) | CN1110304C (xx) |
| AT (1) | ATE243499T1 (xx) |
| AU (1) | AU719075B2 (xx) |
| BR (1) | BR9706214A (xx) |
| CA (1) | CA2216277C (xx) |
| DE (1) | DE69723024T2 (xx) |
| ES (1) | ES2202528T3 (xx) |
| IT (1) | IT1284604B1 (xx) |
| NZ (1) | NZ328783A (xx) |
| ZA (1) | ZA978099B (xx) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
| US20040219210A1 (en) * | 2003-05-01 | 2004-11-04 | Jian-Hwa Guo | Controlled release solid dosage nifedipine formulations |
| WO2006066932A1 (en) * | 2004-12-24 | 2006-06-29 | Lek Pharmaceuticals D.D. | Stable pharmaceutical composition comprising an active substance in the form of solid solution |
| WO2007014393A2 (en) * | 2005-07-28 | 2007-02-01 | Isp Investments Inc. | Amorphous efavirenz and the production thereof |
| EP1942872A2 (en) * | 2005-11-04 | 2008-07-16 | Eastman Chemical Company | Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents |
| US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
| WO2008076780A2 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments Inc. | Amorphous valsartan and the production thereof |
| US8613946B2 (en) * | 2006-12-21 | 2013-12-24 | Isp Investment Inc. | Carotenoids of enhanced bioavailability |
| WO2008092057A2 (en) * | 2007-01-26 | 2008-07-31 | Isp Investments Inc. | Formulation process method to produce spray dried products |
| WO2008092046A2 (en) * | 2007-01-26 | 2008-07-31 | Isp Investments Inc. | Amorphous oxcarbazepine and the production thereof |
| DE102007048705A1 (de) | 2007-10-11 | 2009-04-16 | Bayer Healthcare Ag | Amorphe Formulierung |
| WO2014016842A1 (en) * | 2012-07-23 | 2014-01-30 | Symed Labs Limited | Amorphous coprecipitates of rivaroxaban |
| WO2015051336A1 (en) * | 2013-10-03 | 2015-04-09 | David Wise | Compositions and methods for treating pelvic pain and other conditions |
| CN109730967B (zh) * | 2019-02-19 | 2021-08-03 | 广东工业大学 | 一种硝苯地平固体分散体及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3033919A1 (de) * | 1980-09-09 | 1982-04-22 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung |
| EP0078430B2 (de) * | 1981-10-29 | 1993-02-10 | Bayer Ag | Verfahren zur Herstellung von festen, schnellfreisetzenden Arzneizubereitungen mit Dihydropyridinen |
| DE3376198D1 (en) * | 1983-11-30 | 1988-05-11 | Siegfried Ag | Therapeutic coronary composition in the form of soft gelatine capsules |
| JPS6136213A (ja) * | 1984-07-27 | 1986-02-20 | Rooto Seiyaku Kk | 口腔用組成物 |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| IT1187751B (it) * | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
| DE3738236A1 (de) * | 1987-11-11 | 1989-05-24 | Euro Celtique Sa | Beisskapsel |
| GB8903328D0 (en) * | 1989-02-14 | 1989-04-05 | Ethical Pharma Ltd | Nifedipine-containing pharmaceutical compositions and process for the preparation thereof |
| US5209933A (en) * | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
| GB9200607D0 (en) * | 1992-01-13 | 1992-03-11 | Ethical Pharma Ltd | Pharmaceutical compositions containing nifedipine and process for the preparation thereof |
| CN1120435A (zh) * | 1994-01-04 | 1996-04-17 | 贵州泰康中医保健技术有限公司 | 硝苯吡啶缓释胶囊 |
| CN1129103A (zh) * | 1995-02-14 | 1996-08-21 | 永信药品工业股份有限公司 | 硝苯吡啶剂型的开发 |
| DE19515972A1 (de) * | 1995-05-02 | 1996-11-07 | Bayer Ag | Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung |
| SI9500173B (sl) * | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
-
1996
- 1996-09-27 IT IT96MI001983A patent/IT1284604B1/it active IP Right Grant
-
1997
- 1997-09-09 US US08/925,966 patent/US5871775A/en not_active Expired - Fee Related
- 1997-09-09 ZA ZA9708099A patent/ZA978099B/xx unknown
- 1997-09-12 AU AU37567/97A patent/AU719075B2/en not_active Ceased
- 1997-09-17 DE DE69723024T patent/DE69723024T2/de not_active Expired - Fee Related
- 1997-09-17 ES ES97116153T patent/ES2202528T3/es not_active Expired - Lifetime
- 1997-09-17 AT AT97116153T patent/ATE243499T1/de not_active IP Right Cessation
- 1997-09-17 EP EP97116153A patent/EP0838218B1/en not_active Expired - Lifetime
- 1997-09-18 NZ NZ328783A patent/NZ328783A/en unknown
- 1997-09-22 CA CA002216277A patent/CA2216277C/en not_active Expired - Fee Related
- 1997-09-26 BR BR9706214A patent/BR9706214A/pt active Search and Examination
- 1997-09-26 CN CN97119609A patent/CN1110304C/zh not_active Expired - Fee Related
- 1997-09-29 JP JP9263279A patent/JPH10152440A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE243499T1 (de) | 2003-07-15 |
| AU719075B2 (en) | 2000-05-04 |
| DE69723024D1 (de) | 2003-07-31 |
| US5871775A (en) | 1999-02-16 |
| CN1110304C (zh) | 2003-06-04 |
| DE69723024T2 (de) | 2004-04-29 |
| IT1284604B1 (it) | 1998-05-21 |
| ITMI961983A1 (it) | 1998-03-27 |
| AU3756797A (en) | 1998-04-02 |
| BR9706214A (pt) | 1999-05-04 |
| NZ328783A (en) | 1998-02-26 |
| EP0838218A1 (en) | 1998-04-29 |
| EP0838218B1 (en) | 2003-06-25 |
| CA2216277C (en) | 2003-06-10 |
| ES2202528T3 (es) | 2004-04-01 |
| JPH10152440A (ja) | 1998-06-09 |
| CA2216277A1 (en) | 1998-03-27 |
| CN1183960A (zh) | 1998-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW355683B (en) | Composition containing micronized nebivolol | |
| ZA978099B (en) | Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance. | |
| AU5087290A (en) | Transmembrane formulations for drug administration | |
| EP2103303A3 (en) | Controlled release formulation containing tramadol | |
| HUT60466A (en) | Process for producing amino acid derivatives and pharmaceutical compositions comprising such active ingredient | |
| HUT64065A (en) | Process for producing quinolone- and naphthyridonecarboxylic acid derivatives and pharmaceutical compositions comprising same as active ingredient | |
| CY2285B1 (en) | Liquid compositions containing cyclosporin and process for their preparation | |
| HUP0004050A3 (en) | Itraconazole exhibiting improved solubility, a method of preparing the same and pharmaceutical composition for oral administration comprising the same | |
| IL157963A0 (en) | Hsa-free formulations of interferon-beta | |
| IE894048L (en) | New therapeutically active compound and a process for its¹preparation | |
| ATE148630T1 (de) | Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen | |
| GR3019324T3 (en) | Pharmaceutical chewing-gum containing acetylsalicylic acid | |
| CA2326198A1 (en) | Cosolvent formulations | |
| AU5157590A (en) | Pharmaceutical compositions for oral administration | |
| HUP0100024A3 (en) | Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient | |
| IE64850B1 (en) | Therapeutically active substituted benzimidazole and process for its preparation | |
| AU3318389A (en) | Azelastine-containing medicaments with controlled release of the active substance | |
| HUT50334A (en) | Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient | |
| HUT61024A (en) | Process for producing 10(1-hydroxyethyl)-11-oxo-1-aza-tricyclo/7.2.0.0.3.8/undex-2-ene-2-carboxylic acid esters and pharmaceutical compositions comprising same as active ingredient | |
| HUT54166A (en) | Process for producing 1,1-dioxocefem-4-carbothiol acid derivatives and pharmaceutical compositions comprising same as active ingredient | |
| CS240991A3 (en) | Solid forms for oral administration, said forms containing iphosphamide as active component | |
| GB9711032D0 (en) | Compound as a stimulant for the central nervous system | |
| HUT61740A (en) | Process for producing 2-piperidinyl-pyrimidine-4-carboxamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
| HUT60737A (en) | Process for producing new 1,4-dihydropyridine derivatives and pharmaceutical compositions comprising same as active ingredient | |
| ATE212840T1 (de) | Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung |